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Abstract
Background: Ketamine has been well studied for its efficacy as an analgesic agent. However, intranasal (IN)
administration of ketamine has only recently been studied in the emergency setting. The objective of this study was to
elucidate the efficacy and adverse effects of a sub-dissociative dose of IN Ketamine compared to IV and IM morphine.
Methods: A single-center, randomized, prospective, parallel clinical trial of efficacy and safety of IN ketamine compared
to IV and IM morphine for analgesia in the emergency department (ED). A convenience sample of 90 patients aged
18–70 experiencing moderate-severe acute traumatic pain (≥80 mm on 100 mm Visual Analog Scale [VAS]) were
randomized to receive either 1.0 mg/kg IN ketamine, 0.1 mg/kg IV MO or 0.15 mg/kg IM MO. Pain relief and adverse
effects were recorded for 1 h post-administration. The primary outcome was efficacy of IN ketamine compared to IV
and IM MO, measured by “time-to-onset” (defined as a ≥15 mm pain decrease on VAS), as well as time to and degree
of maximal pain reduction.
Results: The 3 study groups showed a highly significant, similar maximal pain reduction of 56 ± 26 mm for IN
Ketamine, and 59 ± 22 and 48 ± 30 for IV MO and IM MO, respectively. IN Ketamine provided clinically-comparable
results to those of IV MO with regards to time to onset (14.3 ± 11.2 v. 8.9 ± 5.6 min, respectively) as well as in time to
maximal pain reduction (40.4 ± 16.3) versus (33.4 ± 18), respectively.
Conclusions: IN ketamine shows efficacy and safety comparable to IV and IM MO. Given the benefits of this mode of
analgesia in emergencies, it should be further studied for potential clinical applications.
Trial registration: Retrospectively registered on 27 June 2016. ClinicalTrials.gov ID: NCT02817477
Keywords: Intranasal ketamine, Analgesia, Trauma, Morphine, Mass casualty
Background
Opiates are the current mainstay of severe pain relief in
the pre-hospital setting as well as the Emergency
Department (ED). Despite their efficacy, opiates such as
morphine are inconvenient, as they necessitate either
an intravenous (IV) catheter to be placed or an intra-
muscular (IM) injection to be administered. Intranasal
(IN) administration of opiates is gaining momentum
[1–3] but is still uncommon and suffers from most of
the drawbacks of opiates. Opiate administration in
hemodynamically-unstable patients or those with
potential respiratory and airway problems, requires
caution and frequent monitoring. Furthermore, admin-
istration of IM opiates can be inadequate, due to uncer-
tainty of the extent of absorption, rendering IV opiates
the current standard-of-care. The IV route is often-
times complicated by difficult IV catheter placement in
the pre-hospital, military or mass casualty setting or
even during routine ED care, leading to delayed pain
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relief [4]. IN administration of analgesics has been stud-
ied extensively and generally found to be easy, safe and
effective, especially with opiates [1–3].
Ketamine, an NMDA-antagonist has been widely stud-
ied for its efficacy in analgesia and anesthesia. However,
administration of ketamine via the IN route, especially
in adults, has only recently been studied and requires
further elucidation in the acute setting [5, 6]. Recent
studies examining the role of intranasal ketamine for
analgesia in the ED, provided inconclusive results,
reporting that between 56 and 88 % of patients experi-
enced clinically-significant pain relief [5, 6]. The effi-
cacy and side-effect profile of IN ketamine has not yet
been well compared to opiates in both the ED and pre-
hospital setting. Given the significant potential for a
simple, safe and clinically and logistically convenient
mode of analgesia for acute pain, defining IN keta-
mine’s safety and efficacy seems especially important.
This prospective, open label, single-center, randomized
clinical trial was designed to assess the efficacy and
safety of IN ketamine in the ED setting.
Methods
Trial design
This was a single-center, randomized, prospective, open
label, parallel clinical trial of efficacy and safety of IN keta-
mine compared to IV and IM morphine for analgesia in
acute traumatic pain in the ED. A convenience sample of
90 patients aged 18–70 years experiencing moderate to se-
vere orthopedic pain (≥80 mm on a 100 mm visual analog
scale (VAS)) were randomized to receive either IN keta-
mine, IV morphine or IM morphine. Pain was measured
on a 100 mm VAS prior to administration of analgesia
and at 5 min intervals for 1 h following administration.
Adverse effects were recorded. Patients were enrolled dur-
ing times when a trained medical student researcher (see
below) was available for data collection, on a single ran-
dom day each week, during either the morning or evening
shifts. These sampling times were varied to avoid any
selection bias. The study took place between September
2012 and April 2014.
Study setting and population
The study took place at a large, university-affiliated,
Trauma Level I urban hospital serving a population of
over 360,000 residents and over one million daily com-
muters. The ED serves over 140,000 adults annually.
Institutional Review Board approval was received. Trained
medical students collected the data, and were supported
by the ED physicians, nursing staff, and orthopedic sur-
geons. Opiate delivery and informed consent procedures
were performed and collected by licensed medical staff;
IN ketamine administration and data collection was com-
pleted by the student research technicians. Research
assistants performing the actual study procedure were
last-year medical students who had undergone a 1 h tutor-
ial by one of the principal investigators, involving the
study aims and methodology, relevant drug pharmacology,
potential side effects and complications, problem-solving
and drug delivery optimization, research assistant - re-
search subject interaction etc. During the first 3–5 proce-
dures each research assistant was closely supervised by an
experienced researcher, until deemed sufficiently profi-
cient for independent work.
Patients aged 18–70 years, with mild to moderate blunt
trauma (sustained in road, workplace and home accidents)
causing moderate to severe pain (≥80 mm score on a
100 mm VAS) were eligible for participation in the study.
Additional inclusion criteria were: a Glasgow Coma Score
(GCS) of 15, body weight of 50–110 kg, systolic blood
pressure of 90–160 mmHg, heart rate <100 bpm. Patients
were also required to have an American Society of Anes-
thesiologists (ASA) score of 1 or 2, deny head injury, and
deny regular use of opiates. Exclusion criteria included
any analgesia received within the prior 3 h, allergic sensi-
tivity to morphine or ketamine, a large meal ingested
within the previous hour, pregnancy, deviated nasal
septum or trauma to the nose, and a history of a psychi-
atric condition. Despite evidence that ketamine does not
exacerbate intracranial hemorrhage in patients with head
trauma [7–10], patients with head injury complaining of
loss of consciousness, dizziness, vomiting, or nausea were
excluded as well.
Study materials
Ketamine Hydrochloride for Injection 50 mg/mL
(Rotexmedica, Tritau, Germany) was used in the study.
The atomization device used to dispense the medica-
tion was the Intranasal Mucosal Atomization Device
(Wolf Tory Medical, Salt Lake City, UT, USA).
Study protocol
All potentially eligible patients were approached upon
arrival to the ED and asked for their level of pain.
Patients meeting the eligibility criteria were offered par-
ticipation in the study by a physician unaffiliated with
the research. Once written informed consent was ob-
tained, patients were randomized to IN ketamine, IM
morphine or IV morphine, in a 1:1:1 ratio, using a
randomization scheme that utilized the last digit of their
Government-issued Personal Identification Numbers.
Vital signs including blood pressure, heart rate, respira-
tory rate, and oxygen saturation were obtained, and an
initial VAS reading was obtained immediately prior to
administration of analgesia. Patients were then given
either 1 mg/kg IN ketamine, 0.15 mg/kg IM morphine,
or 0.1 mg/kg slow IV bolus of morphine. Patient weight
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was rounded to the nearest five kilograms, and the dose
was calculated accordingly.
IN administration involved visually assuring that the
nares were patent, followed by the administration of
ketamine spray in 0.1–0.2 mL aliquots into each nare
from a 1cc syringe at intervals of 10–30 s. Patients were
instructed to report post-nasal drip of ketamine which
resulted in increased intervals and augmentation of the
angle and distance of the atomization device from the
nare. IV morphine was administered in a slow bolus
over 30–60 s. IM morphine was administered via a
gluteal muscle injection by a registered ED nurse.
Vital signs and VAS measurements were obtained at
5 min intervals for 60 min. For VAS pain-assessments,
patients were approached and asked to mark their pain
level on subsequent 100 mm lines representing pain
from 0 to 100 %. This was self-reported pain and was
not dependent on the researcher. Adverse effects were
recorded at the end of 1 h using the ‘Opiate Related
Symptom Distress Scale’ [11] and included measure-
ments of the presence, frequency, intensity and disrup-
tiveness of 12 common opiate side-effects. Among these
were nausea, vomiting, urinary retention, constipation,
difficulty concentrating, dizziness, confusion, and others.
Patients were then asked to rate overall pain relief on
the VAS, and provide subjective comments if pain relief
was judged by them to be inadequate.
Outcome measures
The primary outcome was effectiveness of IN ketamine
in decreasing pain intensity, compared to IV and IM
morphine. This was measured by the time to achieve-
ment of a clinically meaningful pain reduction (defined
as 15 mm pain reduction on the VAS), degree and time
to maximal pain reduction. A value of 13 mm VAS score
reduction was previously shown to be clinically-
significant [12], and our choice of 15 mm VAS score
reduction was a slightly more conservative value. Sec-
ondary outcomes included adverse effects and overall
patient satisfaction. Time to achievement of a clinically
meaningful pain reduction was defined as the first time-
point at which the patient reported 15 mm of pain
reduction or more. Maximal pain reduction was defined
as the lowest VAS score reported by the patient over the
course of follow-up. The time to maximal pain reduction
was defined as the time at which the patient had the
lowest VAS score over the course of the 1-h follow-up.
Statistics and data analysis
Sample size was determined based on calculations
performed for previous studies examining analgesics in
an ED setting [13, 14]. Random allocation was generated
by the lead student researcher, and the allocation of
patients was done by the student researchers at the time
of patient recruitment. The trial was ended due to lo-
gistical constraints within the department after reach-
ing the minimum sample size calculated based on the
above mentioned study (which included 30+ subjects
in each group).
Descriptive statistics are given as median, mean and
standard deviation for continuous variables and fre-
quency distribution for categorical variables. A compari-
son of treatment group means was performed using a
one-way Analysis of variance (ANOVA). The multiple
comparisons adjustment method of “Hochberg’s GT2”
was employed for pair-wise comparisons between the
groups. Dichotomous side-effects were compared using
the Chi Square test or Fisher Exact test. When results of
the overall test were significant, the False Discovery Rate
method for adjustment of significance level was employed
for pair-wise comparisons between the groups. An ANOVA
with repeated measures was performed to assess the time
trend and difference between the groups with respect to
pain over time measurement. Statistical analysis was
performed by SAS for Windows version 9.2.
Results
Participant flow
As a convenience sample, all patients entering the
orthopedic trauma bay in the ED were approached
when student researchers were available. Data was
collected between September 2012 and April 2014. Of
those approached, 90 patients were randomized to
receive IN ketamine, IV Morphine or IM morphine.
Five patients were lost to follow-up in the IN keta-
mine group due to ED interventions such as casting
or imaging, which precluded the intensive assessment
required for the study. The reason for the dispropor-
tionate IN ketamine subject loss was the more rapid
administration after randomization and consent. Four
patients in the IN ketamine and two patients in the IM
morphine group were excluded due to improper dosing.
Two patients of the IV Morphine group did not receive
the allocated intervention due to improper dosing, and
one patient in the IN ketamine group changed their minds
before the intervention. One patient in the IM MO group
was excluded due to disclosure of chronic opiate use after
intervention (Fig. 1).
Baseline data
Ninety patients were recruited to the study and were ran-
domized to the IM morphine, IN ketamine, or IV mor-
phine study group. Fifteen patients were excluded for
reasons described above, leaving 75 subjects for final ana-
lysis. Mean age of the patient population was 39.4 years
(range 18–68) and 51 of the recruited patients were men
(68.0 %). Table 1 shows the age and gender distribution, as
well as the pre-analgesic pain level for each study group.
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Mean pre-analgesia VAS score for all groups was 91 mm
(95 % CI 72–100 mm), with no significant difference
between groups. There was no significant difference in
patient age, pre-analgesic initial VAS level, or the gender
distribution between the three study groups.
Dosages
The average delivered dose of each drug was equal to
the planned dose, i.e. 1.0 mg/kg for IN ketamine,
0.10 mg/kg for IV MO, and 0.15 mg/kg for IM MO.
Comparative efficacy
Analgesic efficacy was measured via three parameters:
time to onset was the primary efficacy outcome, maximal
pain reduction, and the time to maximal pain reduction.
Time to onset (TTO) was measured as the period of time
until the patient reached a 15 mm VAS score reduction.
In all patients, the average TTO was 16.7 min (95 % CI
13.7–19.7 min). Five patients overall (6.8 %) were non-
responsive to treatment, meaning that they never achieved
the 15 mm VAS pain reduction: 11 % of the IM morphine
group, 4 % of the IN ketamine patients and 4 % of the IV
morphine patients (p = 0.611). TTO was significantly
different (p = 0.000) between groups (Table 2). Average
TTO with IN ketamine was 14.3 min (95 % CI 9.8–
18.8 min), compared to 8.9 min (95 % CI 6.6–11.2 min)
for IV morphine (p = 0.30) and 26.0 min (95 % CI 20.3–
31.7 min) for IM morphine (p = 0.003).
Fig. 1 Participant Flow. The participant flow for this study shows randomization of 90 patients. Patients were lost to follow-up due to tests,
imaging, and other interventions that necessitated that we halt follow-up. Patients were excluded due to dosing errors
Table 1 Population statistics
IN Ketamine (n = 24) IV Morphine (n = 24) IM Morphine (n = 27) p-value
Patient Age (95 % CI) 37.9 (32.3–43.5) 42.9 (38.0–47.8) 37.7 (32.8–42.6) 0.278
Gender
Male 17 (70.8 %) 18 (75.0 %) 16 (59.3 %) 0.455
Female 7 (29.2 %) 6 (25 %) 11 (40.7 %) 0.400
Pre-Analgesic VAS mm on a 100 mm VAS (95 % CI) 90 mm (89.7–90.3) 92 mm (91.7–92.3) 91 mm (90.7–91.3) 0.698
Shows the population statistics of the 75 patients randomized in the trial. No statistical significance was shown between the groups when analyzing patient age,
gender, as well as pre-analgesic VAS levels
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Maximal pain reduction was not significantly differ-
ent among the three groups, with a 56 mm, 59 mm,
and 48 mm pain reduction for the IN ketamine, IV
morphine, and IM morphine groups, respectively (p =
0.3). Time to maximal pain reduction was also not
significantly different for IN ketamine versus either of
the morphine groups: 40.4 min for IN ketamine (95 %
CI 33.9–46.9 min), 33.4 min for IV morphine (95 % CI
26.2–40.6 min), and 46.7 min for IM morphine (95 %
CI 41.1–52.3 min) (p = 0.019 between IM morphine
and IV morphine only).
Pharmacodynamics of pain relief
Pain reduction dynamics were analyzed using a 5-min
pain severity sampling rate (Fig. 2; raw data presented
in Additional file 1: Table S1). There was a nearly
identical pain relief rate in the IV morphine and the
IN ketamine groups, contrasted with the slower
progression of analgesia in the IM morphine group.
Significant differences in pain relief disappeared at
around the 45-min mark.
Patient satisfaction
At the end of the 1-h period of observation, patients
were asked to state their satisfaction with the admin-
istered medication on a 100 mm VAS. IM morphine
and IV morphine had similar results with a mean sat-
isfaction score of 73.9 mm (95 % CI 62.9–84.9 mm),
and 70.2 mm (95 % CI 55.2–85.2 mm), respectively
and 58.7 mm (95 % CI 45.3–72.1 mm) for IN keta-
mine (p = 0.259).
Table 2 Analgesic efficacy
Time to onset




mm on a 100 mm VAS (95 % CI)
Time to max pain reduction
Minutes (95 % CI)
IN Ketamine (n = 24) 14.3 (9.8–18.8) 1 (4 %) 56 mm VAS 40.4 min (33.9–46.9)
IV MO (n = 24) 8.9 (6.6–11.2) 1 (4 %) 59 mm VAS 33.4 min (26.2–40.6)
IM MO (n = 27) 26.0 (20.3–31.7) 3 (11 %) 48 mm VAS 46.7 min (41.1–52.3)
Aggregate 16.7 (13.7–19.7) 5 (6.8 %) 54 mm VAS 40.6 min (36.8–44.4)
P value
IN Ketamine vs. IV MO
0.300 0.611 (DF = 2) 0.300 (DF = 2) 0.386
P value
IN Ketamine vs. IM MO
0.003 0.441
P value
IV MO vs. IM MO
0.000 0.019
Shows the analgesic efficacy in each group. Significant difference is shown in time to onset (time to ≥15 mm VAS reduction) between both the IN ketamine and
IV MO and the IM MO group. IN Ketamine and IV MO were not different. There was no difference in the non-responder rate, nor significance in the maximal pain
reduction between IN ketamine and opiate controls
Fig. 2 Average Pain Reduction in 5 min intervals between groups. The average VAS score for each group was graphed along with standard
deviations. Intranasal Ketamine and IV morphine showed similar pain reduction, with IM morphine showing slower pain reduction over time
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Adverse effects
At the end of one hour, patients were asked to report
symptoms on a standardized ‘Opiate Related Symptom
Distress Scale’ [11]. Of the 12 side-effects queried, only
four yielded significant differences between the groups:
difficulty concentrating, dizziness, confusion, and dry-
ness of the mouth. Table 3 shows the frequency of each
adverse effect in each group. There was a significant in-
crease in reported difficulty concentrating and of dry
mouth between the IN Ketamine and IV and IM mor-
phine. There was less dizziness in patients receiving IM
morphine than IN ketamine, but not IV morphine. Some
patients in the IN ketamine group complained that the
drug “tasted bad,” due to drug runoff into the pharynx.
Finally, while no formal psychomotor testing was
performed, no patient complained of hallucinations, out-
of-body experiences, or emergence reactions sometimes
described with IN ketamine use.
Hemodynamic and respiratory effects
As part of the safety monitoring of patients during the
study, in addition to collection of patient-reported
adverse events, vital signs were measured at 5 min inter-
vals throughout the hour following administration of an-
algesia. Blood pressure, O2 saturation, respirations, and
heart rate were followed. On average, patients treated
with ketamine showed a larger increase and a smaller
decrease in both systolic and diastolic blood pressure
when compared to both morphine control groups.
Respiration rate tended to increase more and decrease
less than IV morphine. While these trends in vital signs
are indicative of the pharmacological properties of
each medication, there was no statistically significant
difference in the changes of vitals for each groups
(See Additional file 2: Table S2).
Discussion
Since its formulation in 1960, ketamine has been used
for a number of indications, such as sedation for painful
procedures [13], endotracheal intubation and analgesia
for severe pain. Due to its benign effects on the cardio-
vascular, respiratory and airway systems, especially im-
portant in fragile or otherwise high risk patients, it has
found a growing role in the induction of anesthesia and
sedation in children and in hemodynamically- compro-
mised patients [15]. In austere conditions and in disaster
and military settings, ketamine has been shown to be
safe and effective for both induction and maintenance of
anesthesia with or without mechanical ventilation for
operations lasting up to 2 h [16]. Ketamine is widely
used for sedation for painful procedures in the ED [13]
as well as for analgesia in trauma [17]. In fact, low-dose
ketamine has been shown effective in treating pain [18],
as well as reducing dependence on opioids [19] in an ED
setting. Finally, Ketamine may have neuroprotective
effects in trauma as it increases cerebral blood flow [20].
Ketamine affects the limbic system and the inhibitory
descending pain pathways. It has the ability to downreg-
ulate the resting state connectivity of pain-processing
related structures in the brain, and upregulate the activ-
ity of pathways involved in descending inhibition of pain.
It is hypothesized that during times of stress, these
inhibitory pathways may be activated to reduce our
perception of pain. Furthermore, ketamine’s downregula-
tion effect within the amygdala may explain its role as a
dissociative anesthetic [21].
Efficacy of pain relief
This study attempted to assess the effectiveness of IN
ketamine in the ED setting in moderate to severe pain
resulting from blunt orthopedic injuries. When com-
paring the three measures of effectiveness, TTO, max-
imal pain relief, and time to maximal pain relief, IN
ketamine provided equal or better pain relief compared
to the standard-of-care morphine. IN ketamine pro-
duced a fast induction of pain relief, clinically compar-
able to an IV bolus of morphine. The ability of IN
ketamine to induce significant pain relief quickly and
effectively is not surprising. IN ketamine showed a
45 % bioavailability, higher than most other delivery
methods [22]. IN ketamine’s clinical efficacy is likely ex-
plained by the absorption of the drug through the nasal
mucosa, allowing it to act on the brain without under-
going first pass metabolism. In a study measuring effi-
cacy and pharmacokinetics, ketamine was measured in
the blood within 2 min of IN administration in far
higher concentrations than the less active metabolite,
norketamine [22].
Table 3 Adverse Effects at 1 h
IN Ketamine (n = 24) IV MO (n = 24) IM MO (m = 27) IN Ketamine v. IV MO IN Ketamine vs. IM MO
Difficulty Concentrating % 58.3 % 20.8 % 22.2 % 0.034 0.027
Dizziness % 79.2 % 50.0 % 22.2 % 0.092 <0.000
Confusion % 50.0 % 12.5 % 18.5 % 0.027 0.061
Dry-Mouth % 25.0 % 79.2 % 63.0 % 0.002 0.027
IN Ketamine showed greater frequency of difficulty in concentrating and fewer levels of dry mouth. IN ketamine and IV MO showed greater levels of dizziness. IN
Ketamine showed greater levels of confusion than IV MO
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Additional effectiveness parameters measured were
maximal pain relief, and the time to achievement of
maximal pain relief. No significant difference was seen
between the three study groups on the maximal pain
relief, with all three groups reducing pain very ad-
equately by approximately 50 mm on the VAS. Pharma-
cokinetic studies of IN ketamine administration showed
maximum concentrations in the blood at 30 min, with
gradual reduction of analgesic effect starting at around
40 min [23]. In our study, IN ketamine reached the point
of maximal pain reduction within an intermediate time
between the IV and IM morphine. Statistically, it was not
significantly different from either group. Taken together,
these results indicate that IN ketamine may provide anal-
gesia clinically equal to IV or IM morphine.
Patient satisfaction
There was no significant difference in patient satisfaction
between the groups.
Relevance to acute trauma and military medicine
Whereas rapid and effective analgesia is of paramount im-
portance in all medical situations, choosing the correct
medication is oftentimes a challenge in severe trauma,
emergency and mass casualty situations. Adverse effects
such as hemodynamic instability and decreased respiratory
drive require alternatives beyond opioids. IV or IM use of
ketamine in the acute pre-hospital, military, or mass cas-
ualty setting has been widely discussed in the literature. A
study of 40 medevac patients receiving either IM or IV
ketamine for pain relief concluded that ketamine is “safe,
effective, and may be more appropriate than the drugs cur-
rently used by pre-hospital providers” [24]. Whereas IV
and IM ketamine have been a mainstay of analgesia care
for severe pain, used by many hospital, pre-hospital and
military medical providers, only recently has the IN route
been actively introduced into this field. The first use of IN
ketamine in the civilian pre-hospital setting, a case report
from 2009, treated a 9-year-old boy with burn injuries, de-
scribing sufficient pain relief on 0.5 mg/kg of IN ketamine
to dress and treat the patient’s wounds en route [25]. More
recently, studies of IN ketamine in the ED have shown its
efficacy and safety in a heterogeneous population of ED
patients, but not specifically orthopedic and trauma [5, 6].
In a pediatric population with acute limb injuries, IN keta-
mine has already been shown to be equally effective and
safe when compared to IN fentanyl [14]. The ease of ad-
ministration and safety profile of ketamine, and the current
challenges of treating pain in acute trauma patients may
indicate that IN ketamine is an effective route of adminis-
tration and analgesic choice for the treatment of civilians
and military personnel experiencing acute trauma.
Adverse effects
There is little evidence in the literature to suggest that
IN ketamine has serious side-effects. Extensive use of IN
ketamine (four sprays per hour over a period of months)
resulted in anosmia in a woman suffering from break-
through oncological pain [26]. In our study, IN ketamine
showed nearly identical rates of adverse effects to that of
IV and IM morphine, none of which were dangerous.
Previous studies reported dizziness as the most common
adverse effect with incidences as high as 52 % [5] and
31 % [6]. Nineteen patients (79 % of the ketamine group)
experienced dizziness shortly after administration of IN
ketamine, but it was transient in nature, universally re-
solving within 7–10 min, and of only mild to moderate
intensity. Increased levels of difficulty concentrating and
confusion in the IN ketamine population mirrored the
drug’s effects as a dissociative anesthetic/analgesic. Pa-
tients reported feeling “disconnected from their pain,” or
“aware but apathetic” to their pain. However, these side-
effects did not preclude patients assessing their satisfac-
tion with IN ketamine as no less than that of morphine.
Study generalizability and limitations
We believe this study is easily generalizable to any ED,
and indeed any pre-hospital or military situation. Since
the pharmacokinetics of ketamine are well studied and
understood, we have simply studied the safety and effi-
cacy of the IN administration of ketamine in the acute
care population. Generalizability of our data may be lim-
ited by our inclusion of only moderate-severe pain
patients (80–100 mm VAS). In fact, many ED patients
were excluded simply because they did not self-report
pain of that intensity. Perhaps expanding to all pain
levels above 60 mm VAS would be more applicable to
clinical practice. Generalizability could also be increased
by expanding the types of injuries studied. This study
examined orthopedic limb and spine injuries; perhaps
the addition of blunt chest injury and rib fractures could
increase clinical utility.
Limitations of this study were mostly technical and
relevant to the IN drug delivery. Atomization of IN keta-
mine was sometimes difficult to control using the syr-
inge system we chose. The amount atomized with every
push of the syringe was somewhat variable, leading
sometimes to runoff into the pharynx. Studies of IN de-
livery show that volumes greater than 300 μl per nostril
may be difficult to absorb through the nasal mucosa,
leading to reduced drug absorption [1]. Furthermore, IN
dosing has been shown to be variable, indicating that fu-
ture work should focus on identifying the proper doses
and drug concentrations as well as delivery devices, for
optimal absorption and efficacy. Our follow-up duration
of 1 h was limited, though geared towards the primary
study endpoints. An additional limitation of this study
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was the lack of researcher blinding. While any study of
this nature would benefit from blinding, the different
routes of administration made blinding complicated in a
busy ED setting without the use of sham IV/IM/IN drug
administration. A blinded study is already underway in
our department, looking at longer - term effects of IN
ketamine as well as treatment for a more diverse patient
population. Finally, while we believe that there is good
generalizability and external validity to this study, due to
the clinically relevant setting we used, larger studies,
looking at more diverse causes of pain are still needed.
Conclusions
IN ketamine showed efficacy and safety comparable to the
current standard-of-care for acute traumatic pain in the
ED, IM and IV morphine. IN ketamine provided rapid
pain relief without causing hemodynamic instability or re-
spiratory side-effects, was easy to administer and may thus
be an important option for ED settings, pre-hospital
trauma management, as well as in battlefield and disaster
medicine. Further studies are needed in order to define
optimal concentrations and doses of IN ketamine, as well
as improved delivery devices able to deliver a controlled
quantity of ketamine to the patient.
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